Roles of HIV-1 Env variable regions in viral neutralization and vaccine development

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 542-553

  Pinter, Abraham ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

HXB2; IIIB derived antigens; Neutralization Epitopes; V3 region; Vaccination

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MICROBIAL DIVERSITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSMISSION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIGEN-ANTIBODY REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 38949186531     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418470     Document Type: Review

References (120)

1. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunder R, Janssens W, van der Groen G. (2000). Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. Journal of Medical Virology. 62:14-24.
2. Berman PW, Gray AM, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, Francis DP, Gorse G, Schwartz DH. (1997). Genetic and immunologic characterization of viruses infecting MN-rgpl20-vaccinated volunteers. Journal of Infectious Diseases. 176:384-397.
3. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78:13232-13252.
4. Bolognesi DP, Matthews TJ. (1998). Viral envelope fails to deliver? Nature. 391:638-639.
5. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. (1994). Cryptic nature of envelope V3 region epitopes, protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology. 68:6006-6013.
6. Broder C, Earl PL, Long D, Abedon ST, Moss B, Doms RW. (1994). Antigenic implications of human immunodeficiency virus envelope quaternary structure: oligomer-specific and - type 1 sensitive monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 91:11699-11703.
7. Burton DR, Desrosiers RC, Donis RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. (2004). HIV vaccine design and the neutralizing antibody problem. Nature Immunology. 5:233-236.
8. Burton DR, Stanfield RL, Wilson IA. (2005). Antibody vs HIV in a clash of evolutionary titans. Proceedings of the National Academy of Sciences of the United States of America. 102:14943-14948.
9. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. (2003). Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300:2065-2071.
10. Candotti D, Rosenheim M, Huraux JM, Agut H. (1997). Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates. Journal of Virology Methods. 64:81-93.
11. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. (1997). Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. Journal of Virology. 71:9808-9812.
12. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. (2005). Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 22:163-173.
13. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. (2007). Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Research and Human Retroviruses. 23:415-426.
14. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ. (1999). Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Journal of Virology. 73:5294-5300,
15. Chesebro B, Wehrly K, Nishio J, Perryman S. (1992). Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparision with T-cell isolates: definition of critical amino acids involved in cell tropism. Journal of Virology. 66:6547-6554.
16. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. Journal of Virology. 79:6528-6531.
17. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV, Jr., Dimitrov DS. (2007). Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gpl40) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology. 363:79-90.
18. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. (1998). Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. Journal of Virology. 72:1552-1576.
19. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. (2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV- 1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection. Journal of Virology, 80:8745-8762.
20. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 303:2019-2022.
21. Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LS, Hendry RM, Yang WP, Barbas CF, 3rd, Burton DR. (1995). Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. Journal of Immunology. 154:893-906.
22. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. (2005). Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases. 191:654-665.
23. Freed EO, Martin MA. (1994). Evidence for a functional interaction between the V1/N2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. Journal of Virology. 68:2503-2512.
24. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. (2005). Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. Journal of Infectious Diseases. 191:666-677.
25. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B. (2007). Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120. Journal of Virology. 81:4886-4891.
26. Gorny M, Williams C, Volsky B, Revesz K, Wang X-H, Burda S, Kimura T, Konings FAJ, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. (2006). Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from cells of individuals infected with non B clades of HIV-1. Journal of Virology. 80:6865-6872.
27. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. (1994). Hump anti-V2 monoclonal antibody that neutral lizes primary but not laboratory isolates of HIV-1. Journal of Virology. 68:8312-8320.
28. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. (2005). Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. Journal of Virology. 79:5232-5237.
29. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. (2002). Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. Journal of Virology. 76:9035-9045.
30. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lamber JS, Corey L, Belsbe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE. (1998). Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. Journal of Infectious Diseases. 177:310-319.
31. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L. (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Journal of Virology. 81:6187-6196.
32. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. (2005). V3: HIV's switch-hitter. AIDS Research and Human Retroviruses. 21:171-189.
33. Haynes BF, Fleming J, St. Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 308:1906-1908.
34. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. (2005). Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Human Antibodies. 14:59-67.
35. He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J. Pinter A. (2002). Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. Journal of Immunology. 169:595-605.
36. Ho DD, Fung MSC, Cao Y, Li XL, Sun C, Chang TW, Sun NC. (1991). Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 88:8949-8952.
37. Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. (2007). Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. Journal of Virology. 81:1424-1432.
38. Hung CS, Vander Heyden N, Ratner L. (1999). Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. Journal of Virology. 73:8216-8226.
39. Hwang SS, Boyle TJ, Lyerly H& Cullen BR. (1991). Identification of envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 253:71-74.
40. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ. (1989). Principal neutralizzing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy of Sciences of the United States of America. 86:6768-6772.
41. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, Desrosiers RC. (2003). Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities. Journal of Virology. 77:9993-10003.
42. Kahn J, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, Sinangil F. (1995). Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. Journal of Infectious Diseases. 171:1343-1347.
43. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. (1994). Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. Journal of Virology. 68:2253-2259.
44. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. (2001). Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the,Position of the gp120 VI/V2 Variable Loops. Journal of Virology. 75:3435-3443.
45. Kolchinsky P, Mirzabekov T, Farzam M, Kiprilov E, Cayabyab M, Mooney LJ, Choe H, Sodroski J. (1991). Adaptation of a CCR5-using, primary human intimmodeficiency virus type 1 isolate for CD4-independent replication. Journal of Virology. 73:8120-8126.
46. Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI, (2007). HIV Molecular Immunology 2006/2007, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico.
47. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. (1996). Quantitative analysis of servin neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology. 70:445-458.
48. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. (2005). Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. Journal of Virology. 79:780-790.
49. Krachmarov CP, Hormen WJ, Lai Z, Bu X, Gorny MK, Zolla-Pazner S, Wang S, Lu S, Pinter A. (2007). Effects of V3 variation and V1/V2 masking on neutralization of a panel of tier 2 clade B Envs by V3-specific monoclonal and polyclonal antibodies. AIDS Vaccine 2007. Antiviral Therapy. 12(Suppl 4): P13-16.
50. Krachmarov Ci, Kayman SC, Honnen WJ, Gorny MK, Zolla-Pazner S, Pinter A. (2006). Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1 type 1. Journal of Virology. 80:7127-7135.
51. Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A. (2001). V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses. 17:1737-1748.
52. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (2000). Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 8:1329-1339.
53. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:648-659.
54. Laman JD, Schellekens MM, Abacioglu YH, Lewis GK, Tersmette M, Fouchier RA, Langedijk JP, Claasen E, Boersma WJ. (1992). Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. Journal of Virology. 66:5175.
55. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, Putney SD. (1990). Conserved sequence, structural elements in the HIV-1 principal neutralizing determinant. Science. 249:932-935.
56. Law M, Cardoso RM. Wilson IA, Burton DR. (2007). Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. Journal of Virology. 81:4272-4285.
57. Leitner T, Foley B, Hahn BH, Marx PA, MCutchan F, J. M, Wolinsky SM, Korber B, (2003). HIV and SIV alignments: http://hiv-web.lanl.gov/ content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html., Los Angeles National Laboratory.
58. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. Journal of Biological Chemistry. 265: 10373-10382.
59. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA. (2006). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of Virology. 80:5211-5218.
60. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology. 79:10108-10125.
61. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. (2006). Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. Journal of Virology. 80: 1414-1426.
62. Ly A, Stamatatos L. (2000). V2 Loop Glycosylation of the Human Immunodeficiency Virus Type1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies. Journal of Virology. 74:6769-6776.
63. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. (1996). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Journal of Infectious Diseases. 173:340-348.
64. McElrath M, Corey L, Greenberg PD, Matthews TJ, Montefiori DC, Rowen L, Hood L, Mullins JI. (1996). Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proceedings of the National Academy of Sciences of the United States of America. 93:3972-3977.
65. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S. (1993). Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology. 67:4932-4944.
66. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. (1996). Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology. 70:427-444.
67. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon S-W, Fung MS, Traincard F, Pincus M, Robey G, Robinson JE, Ho DD, Sodroski J. (1993). Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. Journal of Virology. 67:6136-6151.
68. Moore JP, Yoshiyama H, Ho DD, Robinson JE, Sodroski J. (1993). Antigenic variation in gp120s from molecular clones of HIV-1 LAI. AIDS Research and Human Retroviruses. 9:1185-1193.
69. Moore P, Choge I, Gray E, Ranchobe N, Mlisana K, Karim SA, Williamson C, Morris L, (2007). Role of anti-V1V2 antibodies in autologous neutralization of acute HIV-1 subtype C viruses, AIDS Vaccine 2007. Antiviral Therapy; 12(Suppl 4): OA07-06.
70. Morikita T, Maeda Y, Fijii S-I, Matsushita S, Obaru K, Takatsuki K. (1997). The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. AIDS Research and Human Retroviruses. 13:1291-1299.
71. Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J. (1990). Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. Journal of Virology. 64:3779-3791.
72. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB. (2007). An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 (HIV-1) gp41 recognizes an epitope between those of 2F5 and 4E10. Journal of Virology. 81:4033-4043.
73. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. (2007). Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology. 364:441-453.
74. Pantophlet R, Burton DR. (2003). Immunofocusing: antigen engineering to promote the induction of HW-neutralizing antibodies. Trends in Molecular Medicine. 9:468-473.
75. Pantophlet R, Burton DR. (2006). GP120: Target for Neutralizing HIV-1 Antibodies. Annual Reviews of Immunology. 24:739-769.
76. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. (2003). Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp 120. Journal of Virology. 77:642-658.
77. Pantophlet R, Wilson IA, Burton DR. (2004). Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Engineering Design and Selection. 17:749-758.
78. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC. (1997). Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. Journal of Infectious Diseases. 176:924-932.
79. Pinter A, Honnen W, Lai Z, Bu X, Allen S, Mulenga J, Derdeyn C, (2007). Mapping autologous neutralization targets in newly transmitted clade C primary HIV-1 isolates. AIDS Vaccine 2007. Antiviral Therapy. 12(Suppl 4): OA05-04.
80. Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. (2005). The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when engineered into Envelope proteins derived from neutralization-resistant human immunodeficiency virus type 1 primary isolates. Journal of Virology. 79:6909-6917.
81. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kaymari SC. (2004), The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Journal of Virology. 78:5205-5215.
82. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. (2006). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Journal of Infectious Diseases. 194:1661-1671.
83. Poon AF, Lewis FI, Pond SL, Frost SD. (2007). Evolutionary interactions between N-Linked Glycosylation Sites in the HIV-1 Envelope. PLoS Computional Biology. 3:e11.
84. Quinnan GV, Jr., Zhang PF, Fit DW, Dong M, Alter HJ. (1999). Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Research and Human Retroviruses. 15:561-570.
85. Ren X, Sodroski J, Yang X. (2005). An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. Journal of Virology. 79:5616-5624.
86. Rong R, Bibollet-Ruche F, Mulenga, J, Allen S, Blackwell JL, Derdeyn CA. (2007). Role of V1V2 and other human inummodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. Journal of Virology. 81:1350-1359.
87. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon-M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA. (2007). Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C Human Immunodeficiency Virus type 1. Journal of Virology. 81:5658-5668.
88. Ross TM, Cullen BR. (1998). The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proceedings of the National Academy of Sciences of the United States of America. 95:7682-7686.
89. Sagar M, Wu X, Lee S, Overbaugh J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. Journal of Virology. 80:9586-9598.
90. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL. (2006). Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Research and Human Retroviruses. 22:998-1006.
91. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS. (2007). Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage. PLoS Computational Biology. 3:e58.
92. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. (2002). The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. Journal of Virology. 76:7293-7305.
93. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. (2001). Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 293:1155-1159.
94. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. (2002). The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of (alpha)1→2 Mannose Residues on the Outer Face of gp120. Journal of Virology. 76:7306-7321.
95. Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S. (2007). Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Journal of Virology. 81:3757-3768.
96. Shieh JT, Martin, J, Baltuch G, Malim MH, Gonzalez-Scarano F. (2000). Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. Journal of Virology. 74:693-701.
97. Shotton C, Arnold C, Sattentau Q, Sodroski J, Mckeating JA. (1995). Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the Human Immunodeficiency Virus- Type 1 envelope glycoproiein. Journal of Virology. 69:222-230
98. Spenlehauer C, Saragost S, Fleury HJA, Kim A, Aubertin A-M, Moog C. (1998). Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Journal of Virology. 72:9855-9864.
99. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. (2004). Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 12:193-204.
100. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA. (2006). Crystal Structures of Human Immunodeficiency Virus Type (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity. Journal of Virology. 80:6093-6105.
101. Stanfield RL, Wilson IA. (2005). Structural studies of human HIV-1 V3 antibodies. Human Antibodies. 14:73-80.
102. Sullivan N, Thali M, Furman C, Ho DD, Sodroski J. (1993). Effect of amino acid changes in the V1/V2 region of the Human Immunodeficiency Virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. Journal of Virology. 67:3674-3679.
103. Tonks A. (2007). Quest for the AIDS vaccine. British Medical Journal. 334:1346-1348.
104. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, Birx DL. (1995). Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Research and Human Retroviruses. 11:1379-1391.
105. Vella C, King D. Zheng NN, Fickenscher H, Breuer J, Daniels RS. (1999). Alterations in the V1/V2 domain of HIV-2CBL24 glyco-protein 105 correlate with an extended cell tropism. AIDS Research and Human Retroviruses. 15:1399-1402.
106. Vijh-Warrier S. Pinter A, Honnen WJ, Tilley SA. (1996). Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and tne CD4-binding site. Journal of Virology. 70:4466-4473.
107. Wang N. (1997). The role of gp120 V1/V2 sequence diversity in HIV-1 phenotype and antibody neutralization. Ph.D. Thesis, Sackler Institute of Graduate Biomedical Sciences of New York University School of Medicine.
108. Warrier SV, Pinter A, Honnen WJ, Girard M, Muchmore E, Tilley SA. (1994). A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp 120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. Journal of Virology. 68:4636-4642.
109. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. (2003). Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
110. Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, Shao Y, Mascola JR, Nabel GJ. (2006). Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency vims-1 envelope. Vaccine. 24:4995-5002.
111. Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, Vijh-Warrier S, Tilley SA, McKeating J, Shotton C, Pinter A. (1995). Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. Journal of Virology. 69:2271-2278.
112. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. (1995). Involvement of the V1/V2 variable loop structure in the structure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of Virology. 69:5723-5733.
113. Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, Panet A, Mascola JR, Nabel GJ. (2004). Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. Journal of Virology. 78:4029-4036.
114. Zolla-Pazner S. (2004). Identifying epitopes of HIV-1 that induce protective antibodies. Nature Reviews Immunology. 4:199-210.
115. Zolla-Pazner S. (2005). Improving on nature: Focusing the immune response on the V3 loop. Human Antibodies. 14:69-72.
116. Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. (2007). Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 Envelope. Virology. In press.
117. Zollá-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gomy MK. (2004). The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Research and Human Retroviruses. 20:1254-1258.
118. Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Jr., Parren PW, Burton DR. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and
119. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, Kunert R, Katinger H, Wilson IA, Burton DR. (2004). The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. Journal of Virology. 78: 3155-3161.
120. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. (2001). Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. Journal of Virology. 75:10892-10905.